Copenhagen 2009

Advances in HBV Treatment: 2009

AASLD 2008

Focus on Investigational HBV/HCV Agents

Advances in HBV Treatment With Approved Agents

Milan 2008

Update on Hepatitis B Management

Highlight on Special Hepatic Issues and Populations

Boston 2007

Highlight on Special Hepatic Issues and Populations

Clinical Updates in HBV Treatment

Washington 2007

New Data on Viral Hepatitis and Related Complications

Barcelona 2007

Advances in HBV Treatment: 2007

Highlight on Special Hepatic Issues and Populations

Boston 2006

Clinical Updates in HBV Treatment

Los Angeles 2006

New Data on Viral Hepatitis and Related Complications

HBV Workshop 2006

2006 Update on Hepatitis B Management

Vienna 2006

Updates in HBV Management

Shanghai 2006

New Developments in the Management of Chronic Hepatitis B

Hawaii 2005

Conference Report

San Francisco 2005

HCV Management: Facing New Challenges

Managing HCC and Liver Transplantation

Latest Findings in HBV Management

Bali 2005

New Data on Chronic Hepatitis B

Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B.

Wong VW, Wong GL, Yan KK, et al. Hepatology. 2010;51:1945-1953.

Capsule Summary | Expert Commentary | Abstract | Slides

Long-term efficacy of tenofovir monotherapy for hepatitis B virus–monoinfected patients after failure of nucleoside/nucleotide analogues.

van Bömmel F, de Man RA, Wedemeyer H, et al. Hepatology. 2010;51:73-80.

Capsule Summary | Expert Commentary | Abstract | Slides

Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naive, hepatitis B e antigen–positive patients receiving entecavir.

Jung YK, Kim JH, Lee YS, et al. J Clin Gastroenterol. 2010;Epub ahead of print.

Capsule Summary | Expert Commentary | Abstract | Slides